<?xml version="1.0" encoding="UTF-8"?>
<p id="p0010">As observed at the beginning of other coronaviruses epidemics, such as SARS in 2002 and MERS in 2012 [
 <xref rid="bib1" ref-type="bibr">1</xref>], the search of therapeutic interventions has been intense for the coronavirus disease 2019 (COVID-19). The absence of an effective vaccine, treatment regimen, and managemental guidelines for COVID-19 has been responsible for rapid spread and heavy death toll. The COVID-19 associated mortalities in severe forms were mainly attributed to respiratory failure, probably due to lethal pneumonia caused by rampant inflammation [
 <xref rid="bib2" ref-type="bibr">2</xref>]. The SARS-CoV-2 infection is characterized by an increase in pro-inflammatory and decrease in anti-inflammatory cytokines resulting in a state of cytokine storm syndrome, which in turn leads to the development of acute respiratory distress syndrome (ARDS), shock, multiple organ failure and subsequent death of the individual [
 <xref rid="bib2" ref-type="bibr">2</xref>].
</p>
